LRRN3
Leucine-rich repeat neuronal protein 3
Also known as: FIGLER5, FLJ11129, LRRN3_HUMAN, NLRR3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9H3W5
- Gene
- LRRN3
- Ensembl
- ENSG00000173114
- Chromosome
- 7
- Canonical length
- 708 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
Predicted to act upstream of or within positive regulation of synapse assembly. Predicted to be located in membrane. Predicted to be active in extracellular matrix and extracellular space. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
708 residues, UniProt reviewed canonical sequence.
>Q9H3W5|LRRN3
1 MKDMPLRIHV LLGLAITTLV QAVDKKVDCP RLCTCEIRPW FTPRSIYMEA STVDCNDLGL
61 LTFPARLPAN TQILLLQTNN IAKIEYSTDF PVNLTGLDLS QNNLSSVTNI NVKKMPQLLS
121 VYLEENKLTE LPEKCLSELS NLQELYINHN LLSTISPGAF IGLHNLLRLH LNSNRLQMIN
181 SKWFDALPNL EILMIGENPI IRIKDMNFKP LINLRSLVIA GINLTEIPDN ALVGLENLES
241 ISFYDNRLIK VPHVALQKVV NLKFLDLNKN PINRIRRGDF SNMLHLKELG INNMPELISI
301 DSLAVDNLPD LRKIEATNNP RLSYIHPNAF FRLPKLESLM LNSNALSALY HGTIESLPNL
361 KEISIHSNPI RCDCVIRWMN MNKTNIRFME PDSLFCVDPP EFQGQNVRQV HFRDMMEICL
421 PLIAPESFPS NLNVEAGSYV SFHCRATAEP QPEIYWITPS GQKLLPNTLT DKFYVHSEGT
481 LDINGVTPKE GGLYTCIATN LVGADLKSVM IKVDGSFPQD NNGSLNIKIR DIQANSVLVS
541 WKASSKILKS SVKWTAFVKT ENSHAAQSAR IPSDVKVYNL THLNPSTEYK ICIDIPTIYQ
601 KNRKKCVNVT TKGLHPDQKE YEKNNTTTLM ACLGGLLGII GVICLISCLS PEMNCDGGHS
661 YVRNYLQKPT FALGELYPPL INLWEAGKEK STSLKVKATV IGLPTNMSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LRRN3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 22 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 22 nTPM
- thyroid gland: 18 nTPM
- cerebral cortex: 17 nTPM
- basal ganglia: 16 nTPM
- testis: 14 nTPM
- hypothalamus: 9.8 nTPM
Single-cell type
- epicardial cells: 150 nCPM
- retinal amacrine cells: 122 nCPM
- sertoli cells: 121 nCPM
- adipocytes: 116 nCPM
- leydig cells: 88 nCPM
- adrenal medulla cells: 85 nCPM
Immune cell
- naive CD4 T-cell: 33 nTPM
- naive CD8 T-cell: 31 nTPM
- total PBMC: 6.1 nTPM
- memory CD4 T-cell: 2.7 nTPM
- memory CD8 T-cell: 2 nTPM
- memory B-cell: 0.4 nTPM
Brain region
- cerebral cortex: 31 nTPM
- hypothalamus: 28 nTPM
- basal ganglia: 27 nTPM
- thalamus: 23 nTPM
- cerebellum: 22 nTPM
- amygdala: 21 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.63
- gnomAD pLI
- 0.03
- gnomAD missense Z
- 1.04
- DepMap mean gene effect
- 0.14
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Leucine-rich repeat N-terminal domain
- Cysteine-rich flanking region, C-terminal
- Leucine-rich repeat
- Leucine-rich repeat, typical subtype
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Fibronectin type III
- Immunoglobulin-like domain
- Immunoglobulin I-set
- Immunoglobulin-like fold
- Leucine-rich repeat domain superfamily
- Fibronectin type III superfamily
- Immunoglobulin-like domain superfamily
- Leucine-rich repeat and transmembrane domain-containing protein
- Fibronectin type III domain
- Immunoglobulin I-set domain
- Leucine rich repeat
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LRRN3 as an antibody target. Whether an autoantibody or antibody against LRRN3 could matter depends on whether native LRRN3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LRRN3 is annotated at the cell surface, where native LRRN3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LRRN3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...